CARM (Carisma Therapeutics Inc) נכסים נקיים של החברה

The efficiency of Carisma Therapeutics (CARM) is based on creating stable supply channels for biomaterials for new drugs, as confirmed by the current share prices at -0.05 shown on this chart. Carisma Therapeutics (CARM) is penetrating the personalized cancer therapy segment through the use of macrophages. Despite a narrow development profile, large-scale collaboration with a major industry player supports the business's financial stability.

For long-term risk management, net asset analysis is critical, as it reflects the difference between all assets and liabilities through the company's book value of equity, confirming the issuer's actual solvency. In the case of Carisma Therapeutics (CARM), this indicator demonstrates the financial foundation for scaling the CAR-M platform, where capital growth provides the resource base for the global implementation of high-margin cell therapy.